Tumor immune microenvironment of EGFR-mutant non-small-cell lung cancer and its impact on therapeutic efficacy

被引：4
|
作者：
Matsumoto, Yoshiya [1 ,2 ]
Koh, Yasuhiro [2 ]
机构：
[1] Osaka City Univ, Grad Sch Med, Dept Resp Med, Osaka, Japan
[2] Wakayama Med Univ, Internal Med 3, Wakayama, Japan
来源：
IMMUNOTHERAPY | 2020年 / 12卷 / 07期
关键词：
epidermal growth factor receptor; non-small-cell lung cancer; tumor microenvironment; tumor mutational burden; PD-L1; EXPRESSION; MUTATION INCIDENCE; OPEN-LABEL; PHASE IB; DOCETAXEL; NIVOLUMAB; ATEZOLIZUMAB; BLOCKADE; INFILTRATION; CHEMOTHERAPY;
D O I：
10.2217/imt-2019-0213
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：431 / 438
页数：8
相关论文
共 50 条
  • [21] Nivolumab plus ipilimumab in non-small-cell lung cancer
    Reck, Martin
    Borghaei, Hossein
    O'Byrne, Kenneth J.
    FUTURE ONCOLOGY, 2019, 15 (19) : 2287 - 2302
  • [22] Three Treatments for EGFR-Mutant Non-Small-Cell Lung Cancer with Brain Metastases
    Fan, Y.
    Yu, X.
    Wang, H.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2228 - S2228
  • [23] Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer Reply
    Wu, Yi-Long
    Zhong, Wen-Zhao
    LANCET ONCOLOGY, 2018, 19 (03) : E127 - E127
  • [24] Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non-Small-Cell Lung Cancer
    Naqash, Abdul Rafeh
    Floudas, Charalampos S.
    Aber, Etan
    Maoz, Asaf
    Nassar, Amin H.
    Adib, Elio
    Choucair, Khalil
    Xiu, Joanne
    Baca, Yasmine
    Ricciuti, Biagio
    Alessi, Joao V.
    Awad, Mark M.
    Kim, Chul
    Judd, Julia
    Raez, Luis E.
    Lopes, Gilberto
    Nieva, Jorge J.
    Borghaei, Hossein
    Takebe, Naoko
    Ma, Patrick C.
    Halmos, Balazs
    Kwiatkowski, David J.
    Liu, Stephen V.
    Mamdani, Hirva
    JCO PRECISION ONCOLOGY, 2024, 8
  • [25] Clinical Efficacy of Immune Checkpoint Inhibitors in Older Non-small-Cell Lung Cancer Patients: A Meta-Analysis
    Sun, You-Meng
    Wang, Ying
    Sun, Xin-Xing
    Chen, Jing
    Gong, Zhi-Ping
    Meng, Hai-Yan
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [26] YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer
    Li, Ling-Chen
    Chen, Xie-Wan
    Fang, Ling
    Jian, Chun-Li
    Yu, Yong-Xin
    Liao, Xing-Yun
    Sun, Jian-Guo
    CANADIAN RESPIRATORY JOURNAL, 2023, 2023
  • [27] The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors
    Lee, Ji Yun
    Ku, Bo Mi
    Lim, Sung Hee
    Lee, Min-Young
    Kim, Haesu
    Kim, Moonjin
    Kim, Sungmin
    Jung, Hyun Ae
    Sun, Jong-Mu
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (06) : 903 - 909
  • [28] Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
    Kim, Youjin
    Lee, Se-Hoon
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    Sun, Jong-Mu
    CANCER RESEARCH AND TREATMENT, 2019, 51 (02): : 502 - 509
  • [29] Targeting the Tumor Microenvironment in EGFR-Mutant Lung Cancer: Opportunities and Challenges
    Lim, Jeong Uk
    Jung, Junyang
    Kim, Yeon Wook
    Kim, Chi Young
    Lee, Sang Hoon
    Park, Dong Won
    Choi, Sue In
    Ji, Wonjun
    Yeo, Chang Dong
    Lee, Seung Hyeun
    BIOMEDICINES, 2025, 13 (02)
  • [30] Coexistence of Emphysema With Non-small-cell Lung Cancer Predicts the Therapeutic Efficacy of Immune Checkpoint Inhibitors
    Takayama, Yusuke
    Nakamura, Takashi
    Fukushiro, Yuki
    Mishima, Shohei
    Masuda, Ken
    Shoda, Hiroyasu
    IN VIVO, 2021, 35 (01): : 467 - 474
12345